Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Therapeutic Potential of Cell Penetrating Peptides (CPPs) and Cationic Polymers for Chronic Hepatitis B.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- المصدر:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
- بيانات النشر:
Original Publication: Basel, Switzerland : MDPI, [2000-
- الموضوع:
- نبذة مختصرة :
Chronic hepatitis B virus (HBV) infection remains a major health problem worldwide. Because current anti-HBV treatments are only virostatic, there is an urgent need for development of alternative antiviral approaches. In this context, cell-penetrating peptides (CPPs) and cationic polymers, such as chitosan (CS), appear of particular interest as nonviral vectors due to their capacity to facilitate cellular delivery of bioactive cargoes including peptide nucleic acids (PNAs) or DNA vaccines. We have investigated the ability of a PNA conjugated to different CPPs to inhibit the replication of duck hepatitis B virus (DHBV), a reference model for human HBV infection. The in vivo administration of PNA-CPP conjugates to neonatal ducklings showed that they reached the liver and inhibited DHBV replication. Interestingly, our results indicated also that a modified CPP (CatLip) alone, in the absence of its PNA cargo, was able to drastically inhibit late stages of DHBV replication. In the mouse model, conjugation of HBV DNA vaccine to modified CS (Man-CS-Phe) improved cellular and humoral responses to plasmid-encoded antigen. Moreover, other systems for gene delivery were investigated including CPP-modified CS and cationic nanoparticles. The results showed that these nonviral vectors considerably increased plasmid DNA uptake and expression. Collectively promising results obtained in preclinical studies suggest the usefulness of these safe delivery systems for the development of novel therapeutics against chronic hepatitis B.
- References:
Nature. 1993 Oct 7;365(6446):566-8. (PMID: 7692304)
Biophys J. 1997 Jun;72(6):2763-9. (PMID: 9168050)
J Virol. 1993 Nov;67(11):6507-12. (PMID: 7692081)
J Gen Virol. 2006 Nov;87(Pt 11):3225-3232. (PMID: 17030856)
Cell. 1997 Jan 24;88(2):223-33. (PMID: 9008163)
J Biol Chem. 1994 Apr 8;269(14):10444-50. (PMID: 8144628)
Clin Cancer Res. 2001 May;7(5):1127-35. (PMID: 11350875)
Int J Pharm. 2007 Oct 1;343(1-2):247-54. (PMID: 17611054)
Curr Gene Ther. 2014;14(3):149-60. (PMID: 24828255)
Int J Pharm. 2009 Jun 22;375(1-2):133-9. (PMID: 19481699)
Bioconjug Chem. 2006 Jan-Feb;17(1):90-100. (PMID: 16417256)
J Control Release. 2007 Jun 22;119(3):360-7. (PMID: 17478000)
Folia Histochem Cytobiol. 2014;52(4):257-69. (PMID: 25530464)
Pharm Res. 2011 Apr;28(4):812-26. (PMID: 21161337)
Curr Opin Pharmacol. 2006 Oct;6(5):509-14. (PMID: 16860608)
J Control Release. 2009 Jul 1;137(1):54-62. (PMID: 19303039)
Nat Protoc. 2006;1(2):1001-5. (PMID: 17406337)
Science. 1991 Dec 6;254(5037):1497-500. (PMID: 1962210)
Curr Opin Mol Ther. 2000 Jun;2(3):282-7. (PMID: 11249622)
Nat Biotechnol. 2002 Dec;20(12):1228-33. (PMID: 12426578)
Cell. 1988 Dec 23;55(6):1189-93. (PMID: 2849510)
Annu Rev Med. 2006;57:155-66. (PMID: 16409142)
Am Fam Physician. 2004 Jan 1;69(1):75-82. (PMID: 14727820)
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17780-5. (PMID: 16306261)
Biochemistry. 1997 Apr 22;36(16):5072-7. (PMID: 9125529)
J Hepatol. 2011 Jun;54(6):1286-96. (PMID: 21238516)
Expert Rev Vaccines. 2012 Feb;11(2):189-209. (PMID: 22309668)
Bioconjug Chem. 2006 May-Jun;17(3):750-8. (PMID: 16704214)
J Immunol. 2007 Jul 15;179(2):886-93. (PMID: 17617579)
Gene Ther. 2001 Jun;8(11):874-81. (PMID: 11423935)
Int J Pharm. 2008 Apr 16;354(1-2):39-48. (PMID: 18242018)
Science. 1999 Sep 3;285(5433):1569-72. (PMID: 10477521)
Elife. 2012 Nov 13;1:e00049. (PMID: 23150796)
Bioconjug Chem. 2008 Aug;19(8):1526-34. (PMID: 18646838)
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6669-74. (PMID: 15100412)
Biomacromolecules. 2013 Nov 11;14(11):4071-81. (PMID: 24083483)
J Control Release. 2006 Feb 21;110(3):595-604. (PMID: 16377019)
Virus Res. 2008 Jun;134(1-2):235-49. (PMID: 18339439)
Gastroenterology. 2014 Apr;146(4):1070-83. (PMID: 24361467)
Methods Mol Biol. 2011;751:209-21. (PMID: 21674333)
Antiviral Res. 2012 Nov;96(2):256-9. (PMID: 22999818)
Eur J Pharm Biopharm. 2006 Jan;62(1):17-25. (PMID: 16257520)
APMIS Suppl. 2006;(119):7-55. (PMID: 16930175)
Biomaterials. 2014 Sep;35(29):8450-66. (PMID: 24997481)
Biochem Biophys Res Commun. 2006 Aug 4;346(3):758-67. (PMID: 16781666)
Microb Pathog. 2014 Sep;74:59-62. (PMID: 25128091)
Trends Microbiol. 2000 Sep;8(9):402-10. (PMID: 10989307)
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1864-8. (PMID: 1672046)
Methods Mol Med. 2004;96:261-8. (PMID: 14762276)
Int J Pharm. 2013 Apr 15;447(1-2):182-91. (PMID: 23467080)
Cell. 1988 Dec 23;55(6):1179-88. (PMID: 2849509)
Mol Ther Nucleic Acids. 2017 Dec 15;9:162-169. (PMID: 29246295)
Bioconjug Chem. 2000 Sep-Oct;11(5):619-26. (PMID: 10995204)
PLoS One. 2012;7(11):e48721. (PMID: 23173037)
Int J Pharm. 2008 Jul 9;359(1-2):280-7. (PMID: 18490119)
J Control Release. 2015 Jun 10;207:143-53. (PMID: 25886704)
Biochim Biophys Acta. 2009 Dec;1788(12):2509-17. (PMID: 19796627)
- Contributed Indexing:
Keywords: DNA vaccine; antigen (Ag); antiviral therapy; catonic polymers; cell penetrating peptides (CPPs); chitosan (CS); duck hepatitis B virus (DHBV); gene delivery; hepatitis B; hepatitis B virus (HBV); peptide nucleic acids (PNAs)
- الرقم المعرف:
0 (Antiviral Agents)
0 (Biopolymers)
0 (Cations)
0 (Cell-Penetrating Peptides)
0 (Drug Carriers)
0 (Hepatitis B Vaccines)
0 (Peptide Nucleic Acids)
9012-76-4 (Chitosan)
- الموضوع:
Date Created: 20151204 Date Completed: 20160909 Latest Revision: 20231111
- الموضوع:
20240628
- الرقم المعرف:
PMC4691041
- الرقم المعرف:
10.3390/ijms161226094
- الرقم المعرف:
26633356
No Comments.